Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

News Daily News

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Yael L. Maxwell

December 23, 2016

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Conference News TCT 2016

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Michael O'Riordan

October 31, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2016

Shelley Wood

September 30, 2016

News Features

The Bioresorbable Stent Story So Far: What Promise? What Price?

Michael O'Riordan

August 17, 2016

News Daily News

Timing and Type of Events Post-PCI Have Implications for Prognosis—and Honest Discussions With Patients

Yael L. Maxwell

July 05, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

Proposed Legislation Could Mandate Physician Reporting of Adverse Events With Medical Devices

Yael L. Maxwell

June 14, 2016

News Daily News

Abbott Buys St. Jude Medical for $25 Billion, Gaining More Muscle in Cardiovascular Device Arena

Michael O'Riordan

April 29, 2016

News Daily News

导管室并发症：新的分析精准确定了 ACS 患者术中血栓事件的事件率及风险

Shelley Wood

January 21, 2016

News Daily News

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Shelley Wood

January 21, 2016

News Conference News TCT 2015

Trial Results Often Struggle to Keep Pace With Evolving Technology

Nicole Lou

October 13, 2015

News Conference News TCT 2015

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

October 13, 2015

News Conference News TCT 2015

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

Nicole Lou

October 11, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Features

CMS Penalties Spur Efforts to Reduce 30-Day Hospital Readmissions

July 21, 2015

News Daily News

RIBS IV: EES Surpass DCB for Treatment of In-Stent Restenosis

L.A. McKeown

July 01, 2015

News Daily News

LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease

Yael L. Maxwell

June 26, 2015

News Daily News

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Todd Neale

January 28, 2015

Advertisement

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

TCTMD’s Top 10 Most Popular Stories for September 2016

The Bioresorbable Stent Story So Far: What Promise? What Price?

Timing and Type of Events Post-PCI Have Implications for Prognosis—and Honest Discussions With Patients

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Proposed Legislation Could Mandate Physician Reporting of Adverse Events With Medical Devices

Abbott Buys St. Jude Medical for $25 Billion, Gaining More Muscle in Cardiovascular Device Arena

导管室并发症：新的分析精准确定了 ACS 患者术中血栓事件的事件率及风险

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Trial Results Often Struggle to Keep Pace With Evolving Technology

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

CMS Penalties Spur Efforts to Reduce 30-Day Hospital Readmissions

RIBS IV: EES Surpass DCB for Treatment of In-Stent Restenosis

LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content